arrow
T

Theresa M. Rossouw

university of pretoria
H指数:28
被引数:4,980

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

Humoral and cellular immunogenicity of COVID-19 vaccine boosters in participants with advanced HIV disease
2026-01-070
OAAI
Immunopathogenesis and Therapeutic Implications in Basal Cell Carcinoma: Current Concepts and Future Directions

Steel, H.C.; Rossouw, T.M.; Anderson, R.; Anderson, L.; van Tonder, D.; Smit, T.; Rapoport, B.L. 基底细胞癌的免疫发病机制和治疗意义:当前概念与未来方向。Medicina 2025, 61, 1914. [Google Scholar] [CrossRef]

2025-10-250
OAAI
HIV Resistance to Dolutegravir Varies With Coadministered Agents

Beck, I.A.; Boyce, C.L.; Bishop, M.D.; Oldroyd, A.R.; du Toit, L.; Saimen, A.; Ramarope, K.M.; Hitchcock, S.; du Plessis, N.M.; Mbogo, L.; et al. HIV对多替拉韦的抗药性因联合用药剂而异。临床传染病杂志. 2025; 已接收待发表。 [Google Scholar] [CrossRef]

2025-09-020
PRE
SARS-CoV-2 BA.4/5 infection triggers more cross-reactive FcγRIIIa signaling and neutralization than BA.1, in the context of hybrid immunity

在杂交免疫的背景下,SARS-CoV-2 BA.4/5感染比BA.1触发更多的交叉反应fc γ riiia信号传导和中和

2024-07-231
PRE
Specific plasma microRNAs are associated with CD4+ T-cell recovery during suppressive antiretroviral therapy for HIV-1

在HIV-1的抑制性抗逆转录病毒治疗期间,特定的血浆microrna与CD4 T细胞恢复有关。

AIDS
IF3.1
2024-02-010
OAAI
Despite delayed kinetics, people living with HIV achieve equivalent antibody function after SARS-CoV-2 infection or vaccination
2023-08-034
OAAI